May 12, 2025

Golf Course Proximity Linked to Parkinson's Risk

Living within 1 to 3 miles of a golf course was associated with increased risk of Parkinson's disease.

Conexiant

May 09, 2025

Hand Movements Reveal Autism's Kinematic Signature

Machine learning algorithms can distinguish between patients with and without autism by analyzing finger movements during grasping tasks.

Conexiant

May 09, 2025

Sweetie, Stop: The Harm of Elderspeak

Explore how well-meaning but condescending language like “sweetie” and “dearie” can undermine the dignity of older adults.

KFF Health News

May 08, 2025

FDA Warns Physicians of Tianeptine Dangers

The FDA warns physicians about unapproved tianeptine products that are linked to severe adverse events, including dependence, toxicity, and death.

Conexiant

May 08, 2025

Medical Oddities: Tummy Time for Grown-Ups

This week’s research: tattoos misfire, tea heals, and tummy time makes a comeback.

Conexiant

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

May 01, 2025

FDA Approves Intranasal DHE for Acute Migraine Relief

The FDA has approved Atzumi for the acute treatment of migraine with or without aura in adults.

Conexiant

May 01, 2025

Fas Inhibition Shows Neuroprotective Benefit for GA

An investigational Fas inhibitor demonstrated encouraging results in patients with geographic atrophy (GA) in a phase 1b clinical trial. In the study, eyes treated with ONL1204 (ONL Therapeutics) showed reductions in GA lesion growth at 6 months of up to 50% compared to sham-treated eyes after 2 injections spaced 3 months apart, and a 42% reduction in lesion growth compared to fellow untreated eyes after a single injection.

Retinal Physician

May 01, 2025

Migaldendranib May Move the Needle in AMD, DME

Michael A. Singer, MD, shares early phase 2 data supporting D-4517.2 as a safe and effective subcutaneous therapy, reducing injection burden and preserving vision.

Retinal Physician